New trial
Phase I trial: Zanzalintinib cMet/VEGFR inhibitor with checkpoint inhibitors.
- Trial ID
- NCT06968988 on ClinicalTrials.gov
- Cancer type
- Soft Tissue Sarcoma
- Published in
- New in Oncology - June 16, 2025
This dose-finding study evaluates zanzalintinib combined with ipilimumab and nivolumab for metastatic soft tissue sarcoma in patients with progression on 2nd–4th line therapy. Conducted at Washington University School of Medicine, the trial explores a novel triplet regimen targeting angiogenesis and immune pathways.
More in sarcoma and GIST
-
Trial result · Oct 22, 2026 · NCT04514484
Nivolumab + cabozantinib shows feasible safety and prolonged disease stabilization in a small HIV-positive solid-tumor cohort -
New trial · Oct 8, 2026 · NCT07781891
Phase 2 LX-101 IGF-1R–targeted methotrexate conjugate in R/R Ewing sarcoma/DSRCT -
Trial result · Sep 10, 2026 · NCT03069469
Vimseltinib (CSF1R switch-control inhibitor) delivers 64% ORR in surgery-ineligible TGCT, including post–CSF1/CSF1R-treated patients -
New trial · Aug 13, 2026 · NCT07725380
Phase 1/2 domatinostat class I HDAC inhibitor + sirolimus mTOR inhibitor in R/R sarcoma/osteosarcoma. -
Trial result · Aug 6, 2026 · NCT05218499
Brigimadlin (MDM2–p53 antagonist) Misses PFS Endpoint vs Doxorubicin in 1L DDLPS, Despite Higher ORR